OMGA - Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
- Omega Therapeutics ( NASDAQ: OMGA ) on Thursday said the U.S. FDA had cleared its investigational new drug (IND) application to start a phase 1/2 trial of its lead product candidate OTX-2002 for the treatment of a type of liver cancer called hepatocellular carcinoma.
- The company had submitted the IND to the FDA in mid-June .
- OMGA said the early-to-mid stage trial is expected to launch in H2 2022.
- The trial will evaluate the safety and preliminary antitumor activity of OTX-2002.
- OMGA stock fell 2.1% to $4.25 after hours.
For further details see:
Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002